The Week in Review: April 28, 2017 – May 5, 2017

Friday, May 5, 2017 News Recap Canada Great news from Nova Scotia: Expanded access to and coverage for treatment of chronic hepatitis C is now available under the provincial Pharmacare plan, similar to the new arrangements in BC, Alberta, Ontario, Saskatchewan and Quebec.  The drugs covered are: Epclusa, Daklinza, Sunvepra, Zepatier, Harvoni and Sovaldi. You can read the Nova Scotia Pharmacare Formulary Updates here (Nova Scotia Lists EPCLUSA™ on P...

Louisiana proposes tapping a century-old patent law to cut hepatitis C drug prices

Continuing public concerns over high-priced hepatitis C drugs are taking a new twist as Louisiana’s top health official proposes using an obscure federal patent law to get the medicines at a much lower cost. If successful, other states could reap the benefits. Covering treatment for the 35,000 uninsured and Medicaid-dependent residents with hepatitis C would cost the state $764 million given current drug costs, a staggering sum that would have to be pulle

U.S.: Gilead spars with Merck over hepatitis C $1,000-a-pill royalties

Gilead Sciences, which pioneered a cure for hepatitis C, is trying to fend off a demand by Merck for more than $3 billion in a patent dispute over the liver disease treatment.A compound in Gilead's blockbuster drugs Sovaldi and Harvoni was found by a judge last month to have infringed Merck's patents. Now, a jury must decide whether those patents are still valid, and if so, how much Gilead owes Merck in royalties.Gilead plans to show jurors that scientists

Middle-Income Countries consider voiding hepatitis C drug patents

Physician, patient, and health justice groups including the Initiative for Medicines, Access and Knowledge (I-MAK) are mounting legal challenges to Gilead Sciences' patent to sofosbuvir in several middle-income countries including Argentina, Brazil, China, Russia and Ukraine. Read more...http://www.nytimes.com/2015/05/20/business/high-cost-of-hepatitis-c-drug-prompts-a-call-to-void-its-patents.html...

Sofosbuvir & Ledipasvir price pact for low income countries announced by Gilead

Gilead signs hepatitis C drug (sofosbuvir - SOVALDI and ledipasvir) pact to make treatment available in low income countries (Reuters, Sept. 15, 2014) "U.S. drugmaker Gilead Sciences Inc GILD.O has licensed its hepatitis C drug Sovaldi to seven India-based drugmakers that will sell far cheaper versions of the $1,000-a-pill medicine in 91 developing nations...Gilead said it would also launch its own branded Sovaldi in India at a price of $300 a month. The...